The emergence of peptides in the pharmaceutical business: From exploration to exploitation

EuPA Open Proteomics

Volumn 4, Issue , 2014, Pages 58-69

  Uhlig, Thomas ^a   Kyprianou, Themis ^a   Martinelli, Filippo Giancarlo ^a   Oppici, Carlo Alberto ^a   Heiligers, Dave ^a   Hills, Diederik ^a   Calvo, Xavier Ribes ^a   Verhaert, Peter ^a,b  

^a DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

Drug development; Drug discovery; Peptide drugs; Pharmaceutical industry

Indexed keywords

ACT 1; AM 111; BACITRACIN; CAMOSTAT MESILATE; CBP 501; CBX 129801; CVX 060; EP 1590458B 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOCHOLATE SODIUM; GOSERELIN; INSULIN DERIVATIVE; KINESTATIN DERIVATIVE; LAPSEXD 4; LEUPRORELIN; LIPOSOME; MACROGOL; MORPHINE; NANOCARRIER; NATURAL PRODUCT; OCTREOTIDE; PB 1023; PENICILLIN DERIVATIVE; PEPTIDE; PEPTIDE VACCINE; POLYPEPTIDE ANTIBIOTIC AGENT; POVIDONE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BIOTECHNOLOGICAL PRODUCTION; CLINICAL STUDY; DRUG APPROVAL; DRUG CONTROL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MARKETING; DRUG MIXTURE; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; LARGE SCALE PRODUCTION; MASS SPECTROMETRY; NONHUMAN; PATENT; PEPTIDE ANALYSIS; PEPTIDOMICS; PHARMACODYNAMICS; PHARMACOKINETICS; PROCESS OPTIMIZATION; REGISTRATION; STRUCTURE ACTIVITY RELATION;

EID: 84907242289     PISSN: 22129685     EISSN: 22129685     Source Type: Journal    
DOI: 10.1016/j.euprot.2014.05.003     Document Type: Article

References (67)

1. Andersson L., Blomberg L., Flegel M., Lepsa L., Nilsson B., Verlander M. Large-scale synthesis of peptides. Biopolymers 2000, 55(3):227-250.
2. Andrade F., Videira M., Ferreira D., Sarmento B. Nanocarriers for pulmonary administration of peptides and therapeutic proteins. Nanomedicine 2011, 6(1):123-141.
3. Antosova Z., Mackova M., Kral V., Macek T. Therapeutic application of peptides and proteins: parenteral forever?. Trends Biotechnol 2009, 27(11):628-635.
4. AstraZeneca PLC AstraZeneca annual report and Form 20-F Information 2012 2013, 216.
5. Badiani K. Peptides as drugs. Int Pharm Ind 2012, 4(2):84-90.
6. Baggerman G., Verleyen P., Clynen E., Huybrechts J., De Loof A., Schoofs L. Peptidomics. J Chromatogr B: Analyt Technol Biomed Life Sci 2004, 803(1):3-16.
7. Bond A. Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus. Proc (Bayl Univ Med Cent) 2006, 19(3):281-284.
8. Chen M.C., Sonaje K., Chen K.J., Sung H.W. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 2011, 32(36):9826-9838.
9. Chiasma Chiasma technology overview 2013, [http://chiasmapharma.com/UserFiles/File/Chiasma%20Presentation.pdf].
10. Craik D.J., Fairlie D.P., Liras S., Price D. The future of peptide-based drugs. Chem Biol Drug Des 2013, 81(1):136-147.
11. Csaba N., Garcia-Fuentes M., Alonso M.J. Nanoparticles for nasal vaccination. Adv Drug Delivery Rev 2009, 61(2):140-157.
12. Dillen L., Cuyckens F. Quantitative analysis of peptides with mass spectrometry: selected reaction monitoring or high-resolution full scan?. Mass spectrometry for drug discovery and drug development 2013, 403-425. John Wiley & Sons, Inc.
13. Epand R.M., Vogel H.J. Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1999, 1462(1-2):11-28.
14. Espacenet Patent Search Advanced search 2013, [http://worldwide.espacenet.com/advancedSearch?locale=en_EP].
15. European Commission Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use H. a. Consumers 2001.
16. European Commission Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. H. a. Consumers 2003.
17. European Medicines Agency Assessment report for Bydureon 2011.
18. Falciani C., Lozzi L., Pini A., Bracci L. Bioactive peptides from libraries. Chem Biol 2005, 12(4):417-426.
19. Food and Drug Administration Guidance for Industry for the Submission of Chemistry. Manufacturing, and controls information for synthetic peptide substances. C. f. D. E. a. R. (CDER) and C. f. B. E. a. R. (CBER) 1994, 13.
20. Food and Drug Administration Guidance for Industry on Biosimilars: Q & As regarding implementation of the BPCI Act of 2009: questions and answers Part II 2012, [http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm271790.htm].
21. Fox J.L. Rare-disease drugs boosted by new prescription drug user fee act. Nat Biotechnol 2012, 30(8):733-734.
22. Fox J.L. Antimicrobial peptides stage a comeback. Nat Biotechnol 2013, 31(5):379-382.
23. Goycoolea F.M., Lollo G., Remunan-Lopez C., Quaglia F., Alonso M.J. Chitosan-alginate blended nanoparticles as carriers for the transmucosal delivery of macromolecules. Biomacromolecules 2009, 10(7):1736-1743.
24. Hancock R.E., Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006, 24(12):1551-1557.
25. Hoofnagle A.N., Wener M.H. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods 2009, 347(1-2):3-11.
26. Houghten R. Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery. Nature 1991, 354(6348):84-86.
27. IMS Institute for Healthcare Informatics The global use of medicines: outlook through 2012, 2016.
28. Kammona O., Kiparissides C. Recent advances in nanocarrier-based mucosal delivery of biomolecules. J Control Release 2012, 161(3):781-794.
29. Kaspar A.A., Reichert J.M. Future directions for peptide therapeutics. Drug Discov Today 2013, 18(17/18):807-817.
30. Kiparissides C., Kammona O. Nanotechnology advances in controlled drug delivery systems. Phys Status Sol C - Curr Topics Solid State Phys 2008, 5(12):3828-3833.
31. Lax R. The future of peptide development in the pharmaceutical industry. PharManufacturing: Int Peptide Rev 2013, 10-15.
32. Lewis R.J., Garcia M.L. Therapeutic potential of venom peptides. Nat Rev Drug Discov 2003, 2(10):790-802.
33. Li J., Xu X., Xu C., Zhou W., Zhang K., Yu H., et al. Anti-infection peptidomics of amphibian skin. Mol Cell Proteomics 2007, 6(5):882-894.
34. Li J.W., Vederas J.C. Drug discovery and natural products: end of an era or an endless frontier. Science 2009, 325(5937):161-165.
35. Linden P.K. Vancomycin resistance: are there better glycopeptides coming?. Expert Rev Anti Infect Ther 2008, 6(6):917-928.
36. Lindgren M., Langel U. Classes and prediction of cell-penetrating peptides. Methods Mol Biol 2011, 683:3-19.
37. Lopez-Otin C., Matrisian L.M. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007, 7(10):800-808.
38. Luci D.K., Maryanoff B.E., Lawson E.C., Kinney W.A., Qi J.S., Smith C., et al. Urotensin-II receptor antagonists from peptides to small-molecules: assessment of potency, selectivity, and in vitro ADME properties. Abstracts of papers of the American Chemical Society 2011.
39. Martins S., Sarmento B., Ferreira D.C., Souto E.B. Lipid-based colloidal carriers for peptide and protein delivery - liposomes versus lipid nanoparticles. Int J Nanomed 2007, 2(4):595-607.
40. McDonnell L.A., Heeren R.M.A. Imaging mass spectrometry. Mass Spectrom Rev 2007, 26(4):606-643.
41. Miljanich G.P. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem 2004, 11:3029-3040.
42. Moore A. The big and small of drug discovery. Biotech versus pharma: advantages and drawbacks in drug development. EMBO Rep 2003, 4(2):114-117.
43. Muller R.H., Petersen R.D., Hornmoss A., Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Delivery Rev 2007, 59(6):522-530.
44. Noguchi M., Sasada T., Itoh K. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother 2013, 62(5):919-929.
45. Novartis International AG Novartis Group annual report 2011 2011, 288.
46. Pathan F.K., Venkata D.A., Panguluri S.K. Recent patents on antimicrobial peptides. Recent Pat DNA Gene Seq 2010, 4(1):10-16.
47. Pinkse M.W.H., Evaristo G., Pieterse M., Yu Y., Verhaert P. MS approaches to identify and de novo sequence peptides with post-translational modifications from amphibian defense secretions. EUPA Open Proteomics 2014, [in press].
48. Prideaux B., Dartois V., Staab D., Weiner D.M., Via L.E., Barry C.E., et al. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem 2011, 83(6):2112-2118.
49. Pukala T.L., Bowie J.H., Maselli V.M., Musgrave I.F., Tyler M.J. Host-defence peptides from the glandular secretions of amphibians: structure and activity. Nat Prod Rep 2006, 23(3):368-393.
50. Rendell M. Insulin: moments in history. Drug Dev Res 2008, 69(3):95-100.
51. Riemer A.B., Klinger M., Wagner S., Bernhaus A., Mazzucchelli L., Pehamberger H., et al. Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol 2004, 173(1):394-401.
52. Sakamoto K., Hayashi A., Sakamoto A., Kiga D., Nakayama H., Soma A., et al. Site-specific incorporation of an unnatural amino acid into proteins in mammalian cells. Nucleic Acids Res 2002, 30(21):4692-4699.
53. Sharma S., Mukkur T.K.S., Benson H.A.E., Chen Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci 2009, 98(3):812-843.
54. Shaw C., Hirst D., Chen T., O'Rourke M., Rao P. Bradykinin B2 receptor antagonist peptide from amphibian skin 2004, E.P. Office, Europe.
55. Shaw C. Advancing drug discovery with reptile and amphibian venom peptides - venom-based medicines. Regulars (techniques) 2009, 34-37. The Biochemical Society.
56. Smola M., Vandamme T., Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int J Nanomed 2008, 3(1):1-19.
57. Stern W., Mehta N., Carl S.M. Oral delivery of peptides by peptelligence technology. Drug Dev Delivery 2013.
58. Swietlow A., Lax R. Quality control in peptide manufacturing: specifications for GMP peptides. Chimica Oggi - Chem Today 2004, 22-24.
59. Takeda Pharmaceutical Company Limited Annual report 2012 2013.
60. Talmadge J.E. Pharmacodynamic aspects of peptide administration biological response modifiers. Adv Drug Delivery Rev 1998, 33(3):241-252.
61. Tennessen J.A. Molecular evolution of animal antimicrobial peptides: widespread moderate positive selection. J Evol Biol 2005, 18(6):1387-1394.
62. TMR T.M.R. Peptide therapeutics market - global industry analysis, size, share, growth, trends and forecast 2013, [2012-2018].
63. Tomoda K., Ohkoshi T., Nakajima T., Makino K. Preparation and properties of inhalable nanocomposite particles: effects of the size, weight ratio of the primary nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon properties of nanocomposite particles. Colloids Surf B: Biointerfaces 2008, 64(1):70-76.
64. Vetter I., Davis J.L., Rash L.D., Anangi R., Mobli M., Alewood P.F., et al. Venomics: a new paradigm for natural products-based drug discovery. Amino Acids 2011, 40:15-28.
65. Vlieghe P., Lisowski V., Martinez J., Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov Today 2010, 15(1-2):40-56.
66. Wang L., Brock A., Herberich B., Schultz P.G. Expanding the genetic code of Escherichia coli. Science 2001, 292(5516):498-500.
67. Yamada A., Sasada T., Noguchi M., Itoh K. Next-generation peptide vaccines for advanced cancer. Cancer Sci 2013, 104(1):15-21.